Recently, Gilead Sciences, Inc. (NASDAQ:GILD) announced that its marketing application seeking approval for its candidate cobicistat in the EU has been validated by the European Medicines Agency (EMA).
Cobicistat acts as a “boosting” agent whose addition causes blood levels of protease inhibitors — such as Bristol-Myers’ (NYSE:BMY) HIV drug Reyataz and Johnson & Johnson’s (NYSE:JNJ) Prezista — to increase, thereby enabling the HIV therapy to be dosed once daily. We note that cobicistat only … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards